Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Foundation Medicine (FMI) Stock Price
News articles about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Foundation Medicine earned a news impact score of 0.11 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.0014215313704 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s analysis:
- Technical Facts for Investment in Foundation Medicine, Inc. (FMI) – Wall Street Morning (wallstreetmorning.com)
- Foundation Medicine Announces Final National Coverage Determination (NCD) from the Centers for Medicare … – Business Wire (press release) (businesswire.com)
- Blog Exposure – Foundation Medicine Collaborated with Chugai for Commercialization of FoundationOne CDx(TM) in Japan (finance.yahoo.com)
- Foundation Medicine Inc (FMI) Director Sells $274,015.00 in Stock (americanbankingnews.com)
- Jason Ryan Sells 15,000 Shares of Foundation Medicine Inc (FMI) Stock (americanbankingnews.com)
Shares of Foundation Medicine stock opened at $82.60 on Thursday. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.90. The firm has a market capitalization of $2,980.05, a PE ratio of -18.36 and a beta of -0.21. Foundation Medicine has a fifty-two week low of $29.90 and a fifty-two week high of $87.10.
Several research analysts recently commented on the company. BidaskClub cut Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Thursday, March 15th. Wells Fargo reissued a “market perform” rating and issued a $80.00 price objective (up from $67.00) on shares of Foundation Medicine in a report on Thursday, March 8th. Finally, Zacks Investment Research raised Foundation Medicine from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. Five research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $69.60.
In other news, CEO Troy Cox sold 26,713 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $70.13, for a total transaction of $1,873,382.69. Following the completion of the transaction, the chief executive officer now directly owns 224,345 shares of the company’s stock, valued at $15,733,314.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Robert W. Hesslein sold 1,864 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $119,296.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 294,952 shares of company stock valued at $20,147,318. 2.70% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Foundation Medicine (FMI) Stock Price” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-foundation-medicine-fmi-stock-price/1954673.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.